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Abstract
Clues to Alzheimer disease (AD) pathogenesis come from a variety of different sources in-
cluding studies of clinical and neuropathological features, biomarkers, genomics and animal
and cellular models. An important role for amyloid precursor protein (APP) and its process-
ing has emerged and considerable interest has been directed at the hypothesis that Aβ pep-
tides induce changes central to pathogenesis. Accordingly, molecules that reduce the
levels of Aβ peptides have been discovered such as γ-secretase inhibitors (GSIs) and mod-
ulators (GSMs). GSIs and GSMs reduce Aβ levels through very different mechanisms.
However, GSIs, but not GSMs, markedly increase the levels of APP CTFs that are increas-
ingly viewed as disrupting neuronal function. Here, we evaluated the effects of GSIs and
GSMs on a number of neuronal phenotypes possibly relevant to their use in treatment of
AD. We report that GSI disrupted retrograde axonal trafficking of brain-derived neurotrophic
factor (BDNF), suppressed BDNF-induced downstream signaling pathways and induced
changes in the distribution within neuronal processes of mitochondria and synaptic vesicles.
In contrast, treatment with a novel class of GSMs had no significant effect on these mea-
sures. Since knockdown of APP by specific siRNA prevented GSI-induced changes in
BDNF axonal trafficking and signaling, we concluded that GSI effects on APP processing
were responsible, at least in part, for BDNF trafficking and signaling deficits. Our findings
argue that with respect to anti-amyloid treatments, even an APP-specific GSI may have del-
eterious effects and GSMs may serve as a better alternative.
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Introduction
Alzheimer’s disease (AD), characterized with β-amyloid peptide-containing neuritic plaques
and Tau-containing tangles[1–6], is a neurodegenerative disorder leading to progressive cogni-
tive decline and dementia with increasing impairment of daily functions[3, 7–12]. To date,
there are no disease-modifying treatments for this fatal illness.
Attempts to develop treatments have been informed by neuropathological, genetic, animal
modeling and cell biological observations [9–11, 13–22]. All these sources point to amyloid
precursor protein (APP) and its processing as significant for pathogenesis and to APP process-
ing as a potential target for treatments[3, 12, 21, 23]. One potential target(s) is the processing
of APP that leads to the production of amyloid β peptides (Aβ peptides), which requires the se-
quential cleavage of APP by β-secretase and γ-secretase[9–12, 18, 21]. The 40 and 42 residue-
long Aβ peptides, Aβ40 and Aβ42, are the principal components of amyloid plaques (Fig. 1A).
A large body of cell biological and animal model data has suggested that an increased Aβ42 to
40 ratio may modulate the structure of toxic species and that excessive Aβ40/42 peptides induce
AD-relevant changes in neuronal structure and function [1–6]. The molecular structure(s) that
mediate neuronal effects and their mechanism(s) of action are under active investigation [9,
10, 13–18, 20, 24]. Soluble Aβ40/42 peptides, possibly as oligomers or in higher order assemblies,
may contribute to Aβ toxicity [3, 9–11, 14, 24–33].
Current efforts in drug development have targeted eliminating/reducing the production of
Aβ40 and Aβ42 [2, 7, 8, 32–34, 37, 38]. One approach involves the use of γ-secretase inhibitors
(GSIs) to prevent production of all Aβ peptides [39–43]. However, Phase III clinical trials using
the GSI, semagacestat, were discontinued due to detrimental impacts on both cognition and
daily function[7, 8, 35]. Although the mechanism for the deleterious effect was not defined, the
emergence of clinical findings suggests that inhibition of Notch processing by GSI contributed
to these effects, arguing for the development of Notch sparing GSIs [43–45]. Of note, however,
worsening of cognition by both semagacestat and a reportedly Notch-sparing GSI was recently
demonstrated in the ADmouse model of Tg2576 as well as in wild type mice [46]. An alterna-
tive approach for reducing Aβ42 and Aβ40 levels is to enhance, rather than inhibit, the activity/
processivity of γ-secretase via modulators of this enzyme complex, a class of small molecules
termed γ-secretase modulators (GSMs) (Fig. 1B)[34, 36, 43]. GSMs have been shown to de-
crease levels of Aβ42 and Aβ40 while increasing the levels of shorter Aβ peptides, such as Aβ38,
without affecting total Aβ levels [34, 46–50]. Because shorter Aβ peptides are viewed as non-
or less pathogenic [9–11, 20, 35, 36, 43], GSMs are being pursued as potential anti-amyloid
therapies.
As yet the data for GSI and GSM effects on neurons is limited, leaving uncertain what im-
pact they might have on the structure and function of neurons. To explore this topic we exam-
ined GSI and GSM treatments on a number of neuronal phenotypes. Among which, neuronal
trafficking and signaling of brain-derived neurotrophic factor (BDNF) plays a critical role for
the development and maintenance of neuronal circuits[51–58]. Herein, using cultures of corti-
cal and hippocampal neurons, we examined axonal trafficking and signaling of BDNF and
other selected phenotypes. As the GSI, we used the arylsulfonamide-based BMS-299897[59], a
member of GSI family that includes the Notch sparing GSI avagacestat [7, 41]. The GSM,
sGSM41[36], a methylimidazole-containing arylaminothiazole, is one of a series of closely re-
lated GSM chemotypes [60] that shows increased solubility, ergo the designation sGSM [36].
Our studies provide evidence that GSIs, but not GSMs, disrupted BDNF axonal trafficking and
signaling and induced changes in neuronal morphology.
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Fig 1. Differential effects of BMS-299897 and sGSM41 on APP processing. A: A diagram depicts APP processing and the pathways that GSI or GSM
treatment differentially affects Aβ peptide formation and the production of APP C-terminal fragments (APP CTFs). First, β-secretase or α-secretase cleaves
APP, leading to the production of either β-CTF or α-CTF. Cleavage of β-CTF by γ-secretase at multiple sites yields several Aβ peptides and the APP
intracellular domain (AICD). Cleavage of α-CTF by γ-secretase gives rise to and AICD and the P3 fragment. B: Differential effects of GSI and GSM on the
production of Aβ species and APP β-CTF [34–36]. Rat E18 cortical neurons (DIV7) were treated with GSI BMS-299897 (C) or sGSM41 (D) for 24 hrs. The
GSI Impairs Axonal Transport and Induces Neuronal Dysfunction
PLOS ONE | DOI:10.1371/journal.pone.0118379 February 24, 2015 3 / 24
Materials and Methods
Ethics Statement
All surgical and animal procedures are carried out strictly according to the NIH Guide for the
Care and Use of Laboratory Animals. All experiments have been approved by the University of
California San Diego Institutional Animal Care and Use Committee (Protocol# S09371).
Antibodies and Reagents
Rabbit antibodies against ERK1/2, pAkt1 were from Cell Signaling Technologies. Rabbit poly-
clonal IgGs against phospho-TrkB (pY490) were kindly provided by Dr Moses Chao (NYU),
the mouse monoclonal IgGs against TrkB were from BD. Mouse monoclonal IgGs against
pErk1/2 (E4) were from Santa Cruz. Other antibodies used include: rabbit polyclonal IgGs
against pCREB(ser133) (Cell Signaling), mouse monoclonal IgGs against β-actin, β-tubulin,
MAP2 (Sigma). C-terminal APP rabbit monoclonal IgGs (Epitomics), rabbit polyclonal IgGs
against the C-terminal fragment of APP[34], mouse IgGs against N-cadherin (clone C36)
(BD). Rabbit monoclonal IgGs against Akt1 were from Abgent. Rabbit anti-β-actin antibodies
were from Rockland.
Mouse IgGs against Tau were fromMillipore. Mouse IgGs against GAPDH were from Gen-
Tex. Secondary antibodies conjugated to Alexa for immunostaining, quantum dots 655-strep-
tavidin conjugates (QDs) for live imaging of axonal transport of BDNF were from Invitrogen.
Unlabeled human recombinant BDNF was from Genentech. All culture media, antibiotics and
buffers were from Life Technologies.
The GSI BMS-299897 and the GSM sGSM41 were supplied by Dr S. L. Wagner of UCSD.
BMS-299897 is an arylsulfonamide, whose core structure is shared with the Notch sparing GSI
avagacestat[34, 36, 46]. The sGSM41 (International patent WO 2011/163636 A2)[36], a methy-
limidazole-containing arylaminothiazole, is one of a series of closely related GSM chemotypes
[34]. Both BMS-299897 and sGSM41 were prepared in dimethyl sulfoxide (DMSO). 0.1%
DMSO (final concentration) was used as the vehicle control for all experiments.
Primary neuronal cultures and microfluidic chamber cultures
Rat E17–18 primary embryonic mixed cortical and hippocampal neurons were dissected and
maintained as described [57]. Two-thirds of the media was replaced every 2–3 days until exper-
iments. For imaging experiments, hippocampal neurons were cultured into microfluidic cham-
bers with 450μmmicrogrooves (Xona microfluidics)[57]. For biochemistry experiments,
cortical neurons were cultured in home-made microfluidic biochemistry chambers with
450μmmicrogrooves. For signaling studies, mass cultures of cortical neurons were starved for
2hrs in neurobasal media and were stimulated with 50ng/ml BDNF. Neurons were harvested
and lysed in PBS containing 1% NP-40, 0.1% SDS, 0.1% deoxylcholate, 1mM PMSF (phenyl-
methylsulfonyl fluoride), 0.2mM sodium orthovanadate and protease inhibitor cocktail
(Roche). Axonal signaling assays were performed similarly except that BDNF was added only
to the distal axon chambers. Axonal lysates were collected by adding a small volume of lysis
buffer (15–20 μl) into the distal compartments.
media were harvested and levels of Aβ species (Aβ38, 40, 42) in the media were measured as described in Materials and Methods (n = 3, *P< 0.05, **P<
0.01 using student’s t-test). Treatment with 1μMBMS-299897 or 2.5μM sGSM41 showed the most robust effect and these conditions were used in all other
experiments herein. E: Western blotting analyses showing the processing of two substrates of γ-secretase, APP and N-cadherin, in cortical neurons treated
with vehicle (0.1% DMSO), 1μMBMS-299897, 2.5μM sGSM41 for 24 hrs. F: Quantitative measurement of mRNA levels by real-time PCR in cortical neurons
treated as in E. The mRNA levels are normalized to mRNA levels of β-actin (n = 3, mean±S.E., p values represent results of Student’s t-test).
doi:10.1371/journal.pone.0118379.g001
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Drug treatments and siRNA transfections
Neuronal cultures were treated at indicated DIVs for 24 hrs with 1μM BMS-299897, 2.5μM
sGSM41 or the vehicle DMSO (final concentration: 0.1%) for most of the experiments, or for
different periods of time as indicated in specific experiments. Transfections of siRNAs were
performed on*100,000 neurons at DIV4 using NTER Nanoparticle transfection system
(Sigma) following the protocol provided. The siRNAs used were: 1) siRNA against rat APP
(Sigma: Product# PDSIRNA2D: SASI_Rn01_00086595 with starting sequence at 366), and 2)
the MISSION siRNA Universal Negative Control #1 (Sigma: Cat#SIC001). Knockdown experi-
ments were optimized by examining both mRNA and protein expression of APP. A knock-
down efficiency of*80% at the mRNA level as quantitated with the 7300 Real Time PCR
System (Appiled Biosystems) and*30% at the protein level by immunoblotting was
routinely achieved.
Live Imaging of Quantum dots-labeled BDNF (QD-BDNF)
Monobiotinylated BDNF was prepared in a method similar to that described previously [61].
QD-BDNF, which signals and transports like normal BDNF was prepared as described [57].
We chose QD655 with an emission spectrum that can be visualized in the TexasRed channel.
Following starvation for 2 hrs in neurobasal media, QD-BDNF (0.1nM) was added to the distal
chamber and allowed to incubate for 2 hrs as depicted in Fig. 2A. All images were captured on
a Leica DMI6000B inverted microscope with a 100x oil objective lens with a CCD camera
(Rolera-MGi Fast 1397 from Qimaging). The microscope is equipped with an environmental
chamber (37°C, 5% CO2). Images were collected at 1 frame/s for a total of 2 min per movie.
Ten to twenty movies were collected/condition. For each condition, 75–130 QD-BDNF signals
from at least two independent experiments were analyzed. Kymographs generated from each
movie were analyzed using the MetaMorph Software. Direction of movement was determined
by the angle measurement for each line on kymographs using cut-offs as specified below: retro-
grade (-1 to -89.4), anterograde (<-90.6), and stationary (90±0.5). All live-imaging experi-
ments were performed blindly to minimize bias.
SDS-PAGE, Western blotting
Equal amounts of protein samples were run on 4–12% Novex precast gels (Life Technologies).
For APP CTF detection, 4–20% precast gels were used. Immunoblotting was performed follow-
ing standard practice [62]. All blots were developed using the BioRad Clarity Western ECL
substrate and visualized on a BioRad ChemiDoc XRS+ with the BioRad ImageLab software. All
quantification was taken from blots within the linear range of exposure and all analyses were
performed using the ImageLab software (BioRad).
AβMeso scale assay
Aβ38, 40, and 42 were detected as previously described [34]. Briefly, 500K embryonic cortical
neurons were treated in triplicate in 400μl of media containing various concentrations of drugs
or vehicle. Media was collected 24 hrs later and Aβ peptides in the media were detected using
the Aβ triplex Meso scale assay (Meso Scale Discovery). The amount of Aβ peptides was pre-
sented as percentage of vehicle control.
mRNA extraction and quantification
mRNA levels of Hes1 and Hey1 were measured using cDNA synthesized from total RNAs
(RNAeasy Micro Kit from Qiagen). Quantitative real-time PCR reactions in triplicate were
GSI Impairs Axonal Transport and Induces Neuronal Dysfunction
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Fig 2. BMS-299897, not sGSM41, induces deficits in retrograde axonal trafficking of QD-BDNF. A: Microfluidic chamber cultures of rat E18
hippocampal neurons for live imaging of axonal transport of QD-BDNF. At DIV7, neurons were treated with vehicle, BMS-299-897 or sGSM41 followed by
live imaging as described in Materials and Methods. DA: distal axon; CB: cell body; DR: dendrites; PA: proximal axon. B: Representative kymographs
generated from a 90 sec time lapse series (captured at 1frame/s) of axonal movement of QD-BDNF are shown.C: Distribution of instantaneous velocities of
individual QD-BDNFmolecules moving in the retrograde direction under each treatment condition with the mean values marked as red horizontal lines. Time-
lapse recordings were collected from at least three independent experiments for each treatment conditions with 15–20 separate movies being collected
blindly from each sample. The data represent 70–125 QD-BDNFmolecules. D: Analysis of the average distance travelled by QD-BDNFmolecules for each
treatment condition. E: Breakdown of transport directionalities (Retro: retrograde, Antero: anterograde, and Stationary) of all QD-BDNF signals under each
treatment condition. The percentiles for each direction are shown. The data in D, E represent mean±S.E from three independent experiments. All p values
were calculated using student’s t-test.
doi:10.1371/journal.pone.0118379.g002
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performed for each sample using transcript-specific primers (Qiagen). Minus reverse transcrip-
tase (-RT), minus template, and minus primer controls were included to minimize background
signals. Melting curve analyses were performed to ensure the specificity and quality of the
qPCR amplifications. Expression of Hes1 and Hey1 was calculated using the comparative
threshold (ΔΔCT) method and normalized to GAPDH.
Immunostaining, mitochondria and synaptic vesicle analysis, and
electron microscopy
For mass cultures, neurons were maintained on Poly-L-Lysine-coated coverslips and were
fixed in 4% paraformaldehyde (PFA) in PBS for 15 min. Neurons were then permeabilized in
0.2% Triton X-100 in PBS. Samples were blocked using 3% BSA, 5% goat serum in PBS for 1 hr
at room temperature. Primary antibodies were added in block solution for 1 hr at room tem-
perature or overnight at 4°C. Secondary antibodies were added in 3% BSA for 1 hr at room
temperature. Coverslips were washed and mounted for analysis by microscopy. Images were
captured using Leica DMI6000B inverted microscope with a 100x oil objective lens and were
processed using ImageJ.
Treated neurons were fixed and stained for pCREB with a specific antibody (Cell Signaling).
Images were taken with a 20x objective lens by scanning the cells directly adjacent to the micro-
grooves. ImageJ was used to set the threshold for all pCREB images equally. To determine the
percentage of nuclei that were positive for pCREB, the “analyze particles” function in ImageJ
was used to automatically count the number of Hoechst-stained nuclei and the number of
pCREB-positive nuclei.
Deep Red FMMitotracker (Molecular Probes) was used to visualize mitochondria following
the manufacture’s protocol. A rabbit polyclonal synaptophysin antibody (GenTex) was used to
stain fixed neurons on coverslips. All images were acquired and analyzed blindly. For EM anal-
ysis, neurons were fixed and sectioned at the Cellular and Molecular Medicine Electron Mi-
croscopy Facility at UCSD following a standard EM flat embedding protocol. Images were
acquired on a FEI Tecnai Spirit G2 BioTWIN Transmission Electron Microscope and were
processed using ImageJ.
Statistical analysis
All experiments were repeated at least three times independently. Statistical analyses of results
and calculation of p values were performed using Prism5 (GraphPad Software, La Jolla, CA).
For pairwise comparisons, the Student’s t-test and Mann-Whitney tests were used. For multi-
ple comparisons, the Tukey one way ANOVA test was used.
Results
BMS-299897 and sGSM41 induced markedly different effects on
processing of APP and other γ-secretase substrates
GSIs inhibit production of all Aβ species while increasing the β-carboxyl terminal fragment of
APP i.e. β-CTF [34–36, 46] (Fig. 1B). Unlike GSIs, GSMs selectively prevent the production of
Aβ42 and Aβ40 with a concomitant enhancement of Aβ38 production [34–36]. Furthermore,
GSMs do not appear to cause accumulation of β-CTF [34–36, 46] (Fig. 1B). To confirm the dif-
ferential effect of BMS-299897 and sGSM41 treatment on APP processing in neurons, we mea-
sured the levels of Aβ42, Aβ 40 and Aβ 38, as described in Methods and Materials. BMS-299897
reduced the levels of each of the Aβ peptides. At*1.0 μM, BMS-299897 decreased these pep-
tides to levels ranging from 20 to 50% of the vehicle control (Fig. 1C). sGSM41, on the other
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hand, preferentially reduced Aβ42 and Aβ40 while increasing the levels of Aβ38 (Fig. 1D). Con-
sistent with previous results [34, 36], the total level of Aβ peptides was not markedly changed
by sGSM41, thus there was no apparent inhibition of γ-secretase by sGSM41. At 2.5μM,
sGSM41 essentially eliminated all Aβ42/40 species while increasing Aβ38 to*300% of the level
of vehicle controls. Based on these results, we elected to use a final concentration of 1.0 μM for
BMS-299897 and 2.5μM for sGSM41 in all remaining studies.
To further examine the differences in APP processing, we assessed the impact of BMS-
299897 and sGSM41 on the levels of APP CTFs. In agreement with published reports [34, 59],
treatment of cortical neurons with BMS-299897 increased APP CTFs while sGSM41 treatment
did not (Fig. 1E). These results show that BMS-299897 and sGSM41 exert different effects on
processing of endogenous APP in neuronal cultures.
In addition to APP, γ-secretase acts on a large number of substrates [43, 50, 63, 64], among
which are N-cadherin and Notch[39, 65–68]. We asked if the inhibition of APP processing,
seen with the BMS-299897 but not with the sGSM41, would be seen with these two substrates.
N-cadherin processing was dramatically inhibited by the BMS-299897, but not the sGSM41
(Fig. 1E). Inhibition of γ-secretase has been shown to increase the level of CTFs of Notch and
to impede the translocation of the Notch intracellular domain (NICD) to the nucleus, thus in-
hibiting downstream transcriptional events such as the expression of transcription factors,
Hes1 and Hey1 [46, 66, 68]. We tested BMS-299897 and sGSM41 effects on the expression of
these two factors by quantifying their mRNA levels. Treatment with BMS-299897, but not
sGSM41, significantly decreased Hey1 and Hes1 mRNA levels in cortical neurons (Fig. 1F).
These data are evidence that BMS-299897 is not Notch sparing at the concentration used in
our studies. Taken together, the results show that BMS-299897 and sGSM41 are markedly dif-
ferent in their effects on the processing of γ-secretase substrates in neurons. They confirm inhi-
bition of APP processing by BMS-299897 and enhanced processing of APP by the sGSM41.
BMS-299897, but not sGSM41, induced deficits in retrograde axonal
transport of QD-BDNF in hippocampal neurons
Increasing evidence suggests that accumulation of β-CTF (the carboxyl terminal 99 residues of
APP, also known as C99) disrupts the endocytic pathway [69] and negatively impacts neuronal
function [42, 70–79]. Given the different effects detected for BMS-299897 and sGSM41 on pro-
cessing of APP, and the marked increase in β-CTFs induced by BMS-299897 but not by
sGSM41 (Fig. 1E), we tested for possible effects on axonal trafficking of BDNF-containing en-
dosomes. We measured retrograde axonal transport of quantum-dot conjugated BDNF (QD-
BDNF) in hippocampal neurons grown in compartmentalized microfluidic chambers, as de-
scribed previously[55–57] (also see Fig. 2A). Axonal movement of QD-BDNF in neurons
treated with vehicle, BMS-299897, sGSM41 was captured by live cell imaging (S1–S3 Movies).
Analysis of the corresponding kymographs (Fig. 2B) revealed significant differences. Vehicle
treated cultures demonstrated persistent, processive movement of QD-BDNF, a pattern fully
consistent with earlier findings [55, 57]. In contrast, the BMS-299897-treated cultures showed,
in addition to processive movement, a much greater number of QD puncta that moved antero-
gradely, or switched between anterograde and retrograde trajectories (Fig. 2B). The pattern of
QD-BDNF movement in sGSM41-treated cultures much more closely resembled the vehicle,
with relatively few stationary or anterogradely moving puncta. Fig. 2C plots the instantaneous
retrograde velocity – i.e. the velocity while moving; the average for vehicle controls was*0.8
μm/s, a value consistent with earlier observations[55, 57]. The distribution of instantaneous ve-
locities was lower in BMS-299897-treated neurons with the average speed of*0.3 μm/s, a dif-
ference that was significant (p = 0.017). The distribution of instantaneous velocities in the
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sGSM41-treated cultures was similar to the vehicle-treated neurons and the average was not
significantly different. We further calculated the average distance travelled by QD-BDNF. This
value was significantly reduced by about 40% for BMS-299897-treated samples as compared to
the vehicle control (Fig. 2D). Though there was a trend to lower values in sGSM41-treated
neurons, the difference was not statistically significantly (Fig. 2D). To define the directionality
of axonal movement of QD-BDNF, we sorted and quantified the percentile of individual QD-
BDNF molecules moving retrogradely, anterogradely, or remaining stationary as defined in the
Materials and Methods. We observed that in comparison to the vehicle control, BMS-299897
treatment reduced the portion of QD-BDNF signals moving in the retrograde direction (p =
0.0198) with a concomitant increase in the portion of signals moving in the anterograde direc-
tion (p = 0.0147) (Fig. 2E). In contrast, directionality was not significantly affected by sGSM41
treatment (Fig. 2E). These findings show that the GSI, but not the sGSM, disrupted axonal
transport of BDNF.
BMS-299897, but not sGSM41, inhibited TrkB-mediated signaling in
neuronal cultures
Given that BMS-299897 induced deficits in BDNF axonal transport, this raised the possibility
that the compound might also impact BDNF signaling. We thus examined BDNF signaling in
both mass cultures and compartmentalized cultures of E18 rat cortical neurons; the choice of
cortical neurons was based on the ability to harvest sufficient amounts of protein lysates. As ex-
pected and consistent with earlier findings[34, 46], treatment with BMS-299897, but not
sGSM41, induced accumulation of APP CTFs, while having no apparent impact on the level of
full length APP in mass cultures (Fig. 3A). We then examined by immunoblotting activation
of the TrkB receptor and two downstream signaling pathways, Akt1 (part of the Akt/PI3K sig-
naling cascade) and Erk1/2 (part of the MAPKK signaling cascade). Following addition of
BDNF (50ng/ml), early and sustained activation of TrkB was observed after both BMS-299897
and sGSM41 treatments. The responses varied somewhat across cultures, but there was no sig-
nificant difference in pTrkB levels in comparison with the vehicle control (Fig. 3A and B). Ac-
tivation of Akt1 was also equally robust under all treatment conditions (Fig. 3A and C).
However, activation of Erk1/2 did distinguish the treatments in that BMS-299897-treated neu-
rons responded less robustly than the vehicle at both 5 and 30 minutes (Fig. 3A and D). The
response to BDNF signaling with the sGSM41-treated samples was not significantly different
from the control (Fig. 3A and D).
To explore further the possibility that disrupted trafficking of BDNF in axons was correlated
with changes in signaling, we used a 3-chamber microfluidic device in which adequate amounts
of axonal protein could be extracted (Fig. 3E). Axons were treated with 50ng/ml BDNF for
30 min followed by immunoblotting lysates from distal axons (DA). As indicated, lysates from
this compartment were enriched for Tau, an axonal marker; correspondingly, these lysates
were essentially devoid of MAP2, a dendritic marker protein that was present in lysates of the
cell body chamber (CB) which also contain dendrites (Fig. 3F). BMS-299897 treatment elicited
a much less robust of activation of ERK by BDNF at 5 min, as compared to responses in cul-
tures treated with either vehicle or sGSM41 (Fig. 3G and H). These findings are evidence that
the GSI, but not the GSM, negatively impacted BDNF-induced Erk1/2 signaling.
BMS-299897, but not sGSM41, induced changes in organelles present
in neuronal processes
Given the changes in BDNF trafficking and signaling, it was of interest to explore whether GSI-
induced deficits might be accompanied by structural changes in neuronal processes. We
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Fig 3. Differential effects of BMS-299897 and sGSM41 on BDNF/TrkB-mediated signaling pathways.Rat E18 cortical neurons were either cultured in
12-well plate (mass cultures) (A-D) or in microfluidic biochemistry chambers (E-H) to treat and harvest axons only. Neurons were pretreated with vehicle,
BMS-299897, sGSM41 for 24 hrs followed by stimulation with 50ng/ml BDNF as indicated. Equal amounts of protein lysates were analyzed by SDS/PAGE
and immunoblotting with specific antibodies as indicated (A). Semi-quantitative results are shown for the level of activated TrkB (pTrkB in B), activated Akt1
GSI Impairs Axonal Transport and Induces Neuronal Dysfunction
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examined mitochondria and synaptophysin-positive vesicles. Neurons were treated every
24 hrs with vehicle, BMS-299897 or sGSM41 from DIV4 to DIV7 (Fig. 4A). Mitochondria
were labeled with MitoTracker (Fig. 4B); the density of these puncta and their size, as judged
by their apparent length, were then evaluated (Fig. 4C and D). Relative to the vehicle control,
BMS-299897 treatment reduced mitochondrial density while markedly increasing length
(Fig. 4C and D). Treatment with sGSM41 did not reduce density; indeed, there was a signifi-
cant, albeit small, increase. Unlike BMS-299897, sGSM41 had no effect relative to the vehicle
on mitochondrial length (Fig. 4C and D). In parallel studies, synaptophysin-vesicles were ex-
amined (Fig. 4E). BMS-299897 treatment reduced the density of synaptophysin-positive
puncta and increased their apparent size (Fig. 4F and G). Treatment with sGSM41 had no sig-
nificant effect on either of these measures (Fig. 4F and G).
To further define the effects of BMS-299897 treatment, we examined neuronal processes via
transmission electron microscopy (Fig. 5). Mitochondria, which were readily identified, were
sparse in neurites of vehicle-treated neurons in low magnification (9,300x) images (Fig. 5). At
high magnification (18,500x), mitochondria were localized along microtubules (Fig. 5). Neu-
rons treated with sGSM41 showed no obvious differences in mitochondria as compared to ve-
hicle at either 9,300x or 18,500x magnification (Fig. 5). In contrast, neurons treated with BSM-
299897 displayed striking abnormalities. Specifically, there was abnormal accumulation of mi-
tochondria (marked with  in Fig. 5). Zoom-in images of these stretches revealed that mito-
chondria were neither enlarged nor fused, but rather that separate mitochondria were crowded
together (Zoom-in images in Fig. 5). These findings suggest that the apparent increase in
size of mitochondria with fluorescent imaging was due to focal accumulation. Thus, GSI, but
not GSM, induced changes in organelles that are present and actively trafficked in neuronal
processes, suggesting that GSI effects extend to organelles in addition to BDNF-containing
endosomes.
Extended BMS-299897-, not sGSM41- treatment induced changes in
the morphology of neurons
To examine the possibility that the GSI adversely affected other features of neuronal structure,
we examined early and late stages of dendritic arborization in hippocampal neurons following
treatment with vehicle, BMS-299897, or the sGSM41 for either 3 days (at DIV7) or 8 days (at
DIV12) (Fig. 6A). Neurons were stained with MAP2 antibodies to visualize dendrites and neu-
ronal somas (Fig. 6B). Treatment for 3 days resulted in no significant differences across treat-
ment groups in gross morphology (Fig. 6B), soma size (Fig. 6C), or the number of primary
dendrites (Fig. 6D). However, at 8 days of treatment, changes were evident in BMS-299897-
treated neurons (Fig. 6B). Quantitative analysis revealed a marked increase in soma size for
BMS-299897—treated neurons, as compared to either vehicle- or sGSM41-treated neurons
(Fig. 6C). There was also an increase in the number of primary dendrites in BMS-299987-
treated neurons (Fig. 6D). In addition, Sholl analysis showed a trend toward increased dendrit-
ic complexity in BMS-299897-treated neurons (Fig. 6E). Taken together, the data are further
evidence for changes in neuronal morphology induced by GSI but not GSM.
(pAkt1 inC) and activated Erk1/2 (pErk1/2 in D) (mean±S.E., n = 3 for pTrkB, n = 5 for pAkt1, n = 5 for pERK1/2, *P = 0.04, ***P<0.001 using Student’s t-
test). E: Diagram of microfluidic biochemistry chambers used for axonal signaling assays. F: Western blotting analyses of lysates from the distal axon
chamber (DA) and cell body chamber (CB). Samples from CB samples are enriched for the dendritic protein, MAP2 and samples from DA are enriched for
Tau. Total samples from the distal chambers were compared against 1/4th of lysates from the cell body chamber collected from the same experiment. Both
CB and DA chambers were pretreated with vehicle, sGSM41 or BMS-299897 and only distal axonal chambers were treated with BDNF (50ng/ml) for 0, 5 min.
G: Axonal lysates were analyzed by SDS-PAGE/immunoblotting for the level of pErk1/2, total Erk1/2 and β-actin. The results in G that are normalized against
β-actin (mean±S.E., n = 3, *P<0.05) are shown in H. All signaling data analyzed are from 3 or more separate experiments.
doi:10.1371/journal.pone.0118379.g003
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Reduced APP gene expression rescued axonal transport deficits
induced by BMS-299897 treatment
In view of the fact that APP is a substrate for γ-secretase and that BMS-299897 and sGSM41
exhibited marked difference in APP processing(Fig. 1E) as well as earlier findings for the im-
pact of the APP β-CTF on endocytic trafficking [1, 69, 80], we asked if BMS-299897 effect on
APP contributed to axonal transport deficits. To address this possibility, APP protein levels
were selectively reduced in hippocampal neurons using a specific siRNA prior to BMS-299897
Fig 4. BMS-299897, not sGSM41, alters the distribution of mitochondria and synaptophysin-positive vesicles within processes of rat E18
hippocampal neurons. A: Experimental design for examining distribution of mitochondria and synaptic vesicle precursors within neuronal processes. Rat
E18 hippocampal neurons at DIV4 were treated every 24 hrs with vehicle, BMS-299897 or sGSM41. Neurons at DIV7 were either labeled with MitoTracker
for analysis of mitochondria (B-D) or fixed and stained for synaptophysin with a specific antibody (E-G). B: Representative images of DIC and MitoTracker
under each treatment conditions. The density of mitochondria (C) and the measurement of mitochondrial profile (D) are quantitated and presented (n = 15–20
neurites for vehicle, sGSM41 samples. For BMS-299897-treated samples, n = 95–150 puncta, mean±S.E., ***P<0.001). E: Representative images of DIC
and synaptophysin immmunostaining for each treatment condition. The density of mitochondria (F) and the measurement of mitochondrial profile (G) are
quantitated and presented (For density analysis, n = 29–40 neurites, mean±S.E., *P<0.05. For profile measurement, n = 26–27 puncta). Scale bar = 20μm.
doi:10.1371/journal.pone.0118379.g004
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treatment; axonal BDNF trafficking was then assessed. The siRNA for APP resulted in a de-
crease of*30% at the protein level as compared to the control siRNA (Fig. 7A). A similar re-
duction in APP CTFs was achieved when neurons were subsequently treated with BMS-
299897 (Fig. 7A). In cultures treated with the vehicle together with either the siRNA for APP,
or the control siRNA, there were no significant differences in the directionality of BDNF trans-
port or the average retrograde velocity (Fig. 7B-D; S4–S6 Movies). In contrast, BMS-299897
treatment in the presence of the control siRNA resulted in marked changes in the directionality
Fig 5. BMS-299897, not sGSM41, induces clustering of mitochondria within processes of rat E18 hippocampal neurons. Samples were prepared as
in Fig. 4A. The ultra-structures of hippocampal neurites were examined using transmission electron microscopy as described in Materials and Methods. For
each treatment condition, representative images of 9300x, 18500x and Zoom-in are shown. Asterisk denotes a single mitochondrion, arrows point to
vesicles. EM data were verified by two independent researchers at the Cellular and Molecular Medicine Electron Microscopy Facility at UCSD.
doi:10.1371/journal.pone.0118379.g005
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Fig 6. Sustained treatment with BMS-299897, but not GSM, causesmarked changes in soma size
and dendritic complexity in rat E18 hippocampal neurons. A: Experimental paradigm for examining the
effect of sustained treatment with vehicle, BMS-299897 or sGSM41 on neuronal morphology of rat E18
hippocampal neurons. 3-day treatment and 8-day treatment were chosen to assess early and late changes in
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and velocity of movement relative to the vehicle controls; significantly, the differences were
largely prevented in neurons treated with the siRNA for APP (Fig. 7B-D; S4–S6 Movies).
Thus, in the presence of the siRNA for APP, BMS-299897 had no significant effect on either
average velocity or the directionality of BDNF movement (Fig. 7B-D; S4–S6 Movies). Remark-
ably, the siRNA for APP also prevented the marked*50% decrease in the GSI effect on aver-
age velocity (Fig. 7C).
That reducing APP gene expression prevented the BMS-299897-mediated effects on BDNF
axonal transport suggested that it would also prevent BMS-299897 effects on BDNF-mediated
retrograde signaling. To explore this, neurons cultured in microfluidic chambers were treated
with either APP siRNA or control siRNA followed by treatment with either vehicle or BMS-
299897. BDNF was added only to the axonal chamber for 30 min; neuronal somas in the cell
body chamber were then stained with a specific antibody to pCREB, a transcription factor that
is translocated to the nucleus upon activation by axonal BDNF/TrkB signaling cascades[58,
81]. As predicted, neurons treated with BMS-299897 in combination with the control siRNA
showed significantly less pCREB staining than neurons treated with vehicle + APP siRNA
(Fig. 7E and F), a finding consistent with the earlier documentation of decreased axonal
pErk1/2 levels (Fig. 3G). In contrast, the percentage of nuclei immunostained for pCREB in
cultures treated with BSM-299897 plus the APP siRNA was not significantly different from
those treated with the vehicle plus the APP siRNA (Fig. 7E and F). Thus, reducing APP expres-
sion, including the amount of APP CTFs, prevented changes in BDNF signaling induced by the
GSI. We conclude that the effects of the GSI on axonal trafficking and signaling of BDNF was
mediated, at least in part, by APP and/or APP CTFs.
Discussion
The pathogenesis of AD is complex and likely multifactorial, with a diverse set of pathological
signatures, including those for APP processing [3, 5, 9, 10, 12, 20, 27]. The many changes de-
tected have brought different views as to how the disorder is caused and progresses. The early
involvement of the endosomal pathway might contribute to pathogenesis due to either APP- or
to tau-linked pathology [82–84]. Indeed, the endocytic pathway plays an important role in pro-
cessing APP and in supporting transport of endocytic cargoes. Those cargoes carrying trophic
signals from axons to cell bodies are known to play an important role in establishing, maintain-
ing and modifying synaptic connections [85–88].
Our studies have established that GSI acts through altering APP processing to induce defi-
cits of axonal trafficking and signaling of BDNF. They suggest an important role for APP in
regulating endocytic trafficking and signaling of neurotrophic factors. Our findings are consis-
tent with a recent study demonstrating that APP directly interacts with the two surface recep-
tors for nerve growth factor (NGF): TrkA, p75NTR to mediate endocytosis and signaling by
NGF and its receptors[89]. Significantly, the study has demonstrated that downregulation of
APP leads to reduced cell surface levels of TrkA/p75NTR and results in inhibition of neurite
outgrowth by NGF[89]. Therefore, it is possible that APP impacts neuronal function by regu-
lating endocytic trafficking[80, 89].
Given the role for Aβ peptides, Aβ42 in particular, in both the pathology and pathogenesis
of AD, recent attempts used GSIs to reduce Aβ42 levels. Many GSIs have shown the ability to
neuronal morphology. B: Representative images of MAP2 staining for each conditions at Day 3 or 8. C:
Quantitative analysis of soma size (n = 25–30 neurons, mean±S.E., ***P<0.001). D: Quantitative analysis of
number of primary dendrites (n = 17–25 neurons, mean±S.E, ***P<0.001). E: Sholl analysis of neuronal
tracings for 8 day treatment with vehicle, BMS-299897 or sGSM41.
doi:10.1371/journal.pone.0118379.g006
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Fig 7. Knockdown of APP rescues deficits in velocity and directionality of axonally transported QD-BDNF induced by BMS-299897. A: Western
blotting analysis of typical siRNA-mediated knockdown effect on full length APP and APP CTFs. Rat E18 hippocampal neurons (DIV5) were transfected with
siRNA against APP or control siRNA for 72 hrs followed by drug treatment for 24 hrs. On average, the protein levels of APP and APP CTF were knocked
down to 70% of normal levels.B: Live imaging of axonal transport of QD-BDNF was performed as in Fig. 2and representative kymographs of QD-BDNF
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markedly reduce the levels of Aβ42 as well as shorter Aβ peptides [38–40, 43, 44, 68, 90, 91].
However, patients treated with GSI suffered from weight loss, increased skin cancer and infec-
tions [7, 8], in addition to worsening cognition. Similar memory deficits were found using GSIs
in AD mice as well as in wild type mice [42, 46]. In treated subjects, pathological changes con-
sistent with inhibition of Notch raised the possibility that this was responsible for treatment
failures [7, 8]. Accordingly, an attempt to produce APP specific γ-secretase inhibitors was sug-
gested [43, 44, 91].
The studies reported herein argue that the use of an APP specific GSI will still have deleteri-
ous effects on neuronal structure and function. It is possible that a potent GSI used at clinically
relevant concentrations, lower than those we employed, may minimize unwanted effects.
Given that inhibition of APP processing, the intended purpose of GSIs, can now be shown to
result in unwanted and possibly degenerative neuronal changes possibly through accumulation
of APP CTFs, even an APP-specific GSI might be toxic. In contrast, the findings for the sGSM
tested here showed the ability to reduce the levels of Aβ42 and Aβ40 without significantly im-
pacting any of the neuronal phenotypes examined, including those for BDNF trafficking
and signaling.
GSIs and GSMs both reduce the production of Aβ42 and Aβ40 but via distinct mechanisms
[35, 91]. GSIs inhibit production of all Aβ species; GSMs reduce Aβ42 and Aβ40 and increase
the levels of smaller Aβ species, such as Aβ38 [34, 36] (also see Fig. 1A and B). While the GSI
resulted in a marked increase in the level of APP CTFs, no increase was seen with the sGSM
(also see Fig. 1E). Our studies show that the GSI and sGSM had different effects on a number
of neuronal phenotypes. First, the GSI significantly impaired axonal trafficking while the
sGSM did not. Second, differences in endosomal transport of BDNF were observed for velocity,
net distance, and directionality with the GSI but not the sGSM. Third, changes in Erk1/2 sig-
naling downstream from BDNF were associated with the GSI but not with the sGSM. Since ret-
rograde axonal signaling of BDNF plays a critical role in neuronal maintenance and function
[52, 53, 58, 81, 85, 92, 93], we reasoned the GSI would invoke other downstream consequences,
including dysregulation of gene expression needed for the maintenance of neuronal circuits.
Indeed, the GSI-mediated effect on BDNF-induced Erk1/2 activation and nuclear translocation
of pCREB are evidence for this possibility. Further distinguishing the GSI from the sGSM were
changes on the structure of organelles in neuronal processes involving both mitochondria and
synaptophysin-positive vesicles. In GSI-treated cultures, there was a decrease in density of indi-
vidual mitochondrial puncta together with accumulation and abutment of mitochondria in
processes. The same pattern was seen for synaptic vesicles, a decrease in the apparent density
of individual puncta and an increase in their size.
Although it is not clear how changes in neurons were produced by the GSI but not the
sGSM, our findings point to a role for APP CTFs. This is supported by differences in APP pro-
cessing by the GSI and sGSM: While both reduce Aβ species, only the GSI increases APP CTFs
levels. In addition, GSI-induced changes were prevented by reducing APP gene expression.
Consistently, recent studies showed that altered APP processing, including overexpression of
movement (60 sec) within axons are shown for each condition. Retrograde direction is indicated. Analysis of QD-BDNF for average velocities (C) and
directionality of QD-BDNFmovement (D) revealed that knocking down APP prior to BMS-299897 treatment partially rescued the deficits in both the velocities
and directionality of QD-BDNF as seen previously. 15–20 separate movies were collected and analyzed for each chamber. The data represent 50–130 QD-
BDNFmolecules (mean±S.E.). Neurons that were cultured in microfluidic chambers were transfected with siRNA and treated with BMS-299897 as inA.
BDNF (50 ng/ml, final concentration) was added to the distal axon chambers only for 30 min. Neurons were fixed and stained for pCREB using a specific
antibody. The nuclei were stained with the Hoechst dye. Representative images are shown in E and quantitative analysis of the percentage of nuclei that
were pCREB-positive is shown in F (mean±S.E., n = 10 images, **P = 0.004). All images were obtained on a Leica DMI6000B inverted microscope (scale
bar = 50μm).
doi:10.1371/journal.pone.0118379.g007
GSI Impairs Axonal Transport and Induces Neuronal Dysfunction
PLOS ONE | DOI:10.1371/journal.pone.0118379 February 24, 2015 17 / 24
APP CTFs, changed APP trafficking [94] and induced organelle accumulation [95–97] and mi-
tochondrial dysfunction [98–101]. We cannot rule out contributions by γ-secretase substrates,
other than APP, in the context of GSI treatment. As one example, GSI-induced changes in den-
dritic arborization are consistent with earlier reports for inhibition of Notch processing [66, 68,
94].
The most salient outcome of our study is that GSI-mediated disruption of BDNF trafficking
and signaling point to GSIs compromising an important neuronal function. Whether or not
this played a role in the failure of GSI Phase III clinical trials for treatment of AD [7, 8, 63], or
for GSI-induced changes in cognition in animal models is uncertain [42, 46, 70, 71]. But the
data suggest that changes in APP processing may create unwanted effects. Nevertheless, in a re-
cently completed large Phase III clinical trial, patients receiving the GSI semagacestat at a
lower dose failed to improve cognition. And at a higher dose, functional ability in AD patients
became significantly worsening as compared to patients receiving placebo. In addition, severe
adverse effects including skin cancers, infections etc were observed with the use of semagacestat
in human subjects [8]. Furthermore, in animal studies subchronic dosing with either GSIs or
Nortch-sparring GSIs impaired normal cognition in 3-month-old Tg2576 AD mice and even
in normal wild type mice[46]. GSIs did not rescue the deficits of memory deficits in a mouse
model of familial Danish dementia (FDD) [42]. Taken together, these results strongly suggest
that accumulation of APP CTFs, even in the absence of Aβ peptides, caused by GSI treatment,
posts significant toxic effects to synaptic function and cognition, among other adverse effects.
Accordingly, future attempts to inhibit γ-secretase activity must at the very least examine
changes in APP processing and the potential effects of these changes on neuronal function.
In contrast to GSIs, sGSM had little effects on neuronal function in the assays we performed,
and could potentially serve as a better therapeutic alternative. This conclusion is supported by
other observations pointing to the potential value of GSMs as anti-amyloid based drug thera-
pies [35, 36, 63, 64, 102]. GSMs such as sGSMs[34–36] and EVP-0015962[103] decreases Aβ42
with no apparent effects on either the total Aβ peptides or the level of APP CTFs. Both classes
of GSMs have been shown effective in reducing Aβ aggregates, amyloid plaques, inflammatory
markers. And most importantly, they have been shown effective in improving cognitive deficits
in Tg2576 AD mice[34, 103]. However, given the lessons learned with the GSI endeavors, it is
absolutely imperative to carefully examine both in vitro and in vivo the impact of GSMs on
neuronal structure and function prior to their clinical application.
Supporting Information
S1 Movie. QD-BDNF transport in vehicle-treated hippocampal neurons. QD-BDNF move-
ment within the microgroove area of the chamber. Signals that were moving to the right indi-
cate movement in the retrograde direction towards the cell while left-moving signals represent
anterograde transport. Signals that showed no movement represent stationary vesicles.
(AVI)
S2 Movie. QD-BDNF transport in BMS-299897-treated hippocampal neurons.QD-BDNF
movement within the microgroove area of the chamber. As in 1, signals that were moving to
the right indicate movement in the retrograde direction towards the cell while left-moving sig-
nals represent anterograde transport. Signals that showed no movement represent stationary
vesicles.
(AVI)
S3 Movie. QD-BDNF transport in sGSM41-treated hippocampal neurons. QD-BDNF
movement within the microgroove area of the chamber. As in 1, signals that were moving to
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the right indicate movement in the retrograde direction towards the cell while left-moving sig-
nals represent anterograde transport. Signals that showed no movement represent
stationary vesicles.
(AVI)
S4 Movie. QD-BDNF transport in Vehicle + APP siRNA-treated hippocampal neurons.
QD-BDNF movement within the microgroove area of the chamber. As in 1, signals that were
moving to the right indicate movement in the retrograde direction towards the cell while left-
moving signals represent anterograde transport. Signals that showed no movement represent
stationary vesicles.
(AVI)
S5 Movie. QD-BDNF transport in BMS-299897 + ctrl siRNA-treated hippocampal neu-
rons. QD-BDNF movement within the microgroove area of the chamber. As in 1, signals that
were moving to the right indicate movement in the retrograde direction towards the cell while
left-moving signals represent anterograde transport. Signals that showed no movement repre-
sent stationary vesicles.
(AVI)
S6 Movie. QD-BDNF transport in BMS-299897 + APP siRNA-treated hippocampal neu-
rons. QD-BDNF movement within the microgroove area of the chamber. As in 1, signals that
were moving to the right indicate movement in the retrograde direction towards the cell while
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